Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ENSG · against 158 other Healthcare companies of similar size
Ranked #61 of 159 · scores higher than 61% of peers
Bars: peers in each 10-point band of the valuation score23 peers with a valuation score of 60–69, including ENSG · Click a bar to see the companies
Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | ENSG | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 158 reported | 3.5% | 2.6% | 66% | 30% | |
| EBITDA yieldHigher is better · 158 reported | 4.7% | 4.7% | 50% | 50% | |
| Free cash flow yieldHigher is better · 94 reported | 3.9% | 2.2% | 72% | 20% | |
| Book yieldHigher is better · 157 reported | 23.2% | 18.6% | 58% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 5 | 11.6B USD | 94 | 58 | |
| 56 | 10.4B USD | 63 | 70 | |
| 59 | 7.0B USD | 62 | 57 | |
| 59 | 4.7B GBP (≈$6.1B) | 62 | 49 | |
| 61 | 626.0B INR (≈$7.5B) | 61 | 68 | |
| 61 | 10.6B USD | 61 | 64 | |
| 63 | 77.1B DKK (≈$11.6B) | 60 | 47 | |
| 63 | 10.7B USD | 60 | 65 | |
| 65 | 16.7B CHF (≈$19.2B) | 59 | 47 | |
| 66 | 73.2B SAR (≈$19.8B) | 58 | 56 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score